RecruitingEarly Phase 1NCT07767370

ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea

A Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea

Sponsor

The Second Hospital of Nanjing Medical University

Enrollment

36 participants

Start Date

Jul 20, 2026

Study Type

INTERVENTIONAL

Conditions

UC - Ulcerative Colitis Diarrhea Chronic

Summary

This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ND-12, a drug called ND-12/H-6, and others for people with diarrhea chronic and uc - ulcerative colitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGmesalazine

Take 4 melesalazine capsules each time, 3 times a day. Continue for 14 days.

DRUGND-12

Take 1 ND-12 capsule and 3 blank capsules each time, 3 times a day. Continue for 14 days

DRUGND-12/H-6

Take 1 ND-12 capsule and 3 H-6 capsules each time, 3 times a day. Continue for 14 days

Locations(1)

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07767370

Related Trials

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

NCT0685072732 locations

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT070894201 location

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

NCT073851311 location

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT070350411 location